Mum and daughter to take on huge abseiling challenge
Beth and Daisy Hunt, from Fareham, are taking on the "breathtaking" challenge on the 170-metre Spinakker Tower in the Brighterway Charity Abseil Challenge this month.
They will be representing Team UNLOC at the challenge on June 21 and 22.
They hope to raise vital funds for Brighterway, the charity supporting mental health and wellbeing across Hampshire and Isle of Wight Healthcare NHS Foundation Trust.
Beth, who works for UNLOC, said: "I think we'll power through, even though it's quite scary.
"I heard about the abseil through work and I'm one of those people who says 'yes' and then thinks about it later.
"I said to Daisy, 'Well, you can do it too.' And I think with Daisy there, I'll be able to do it."
Her 15-year-old daughter added: "Sometimes I have a fear of heights, so it's a good thing to overcome it - and a cool experience as well.
"It's something you'll always remember… and also something that really matters.
"One small donation can go a long way for someone who needs support."
READ MORE: Former psychiatric patient backs major mental health fundraising appeal
Beth has done adventurous things before, including bungee jumping in New Zealand and hiking Snowdon.
However, she says this feels different.
"Since having kids, I think your mindset changes.
"But doing this with Daisy is important. We're very close, and it's about making memories."
Beth and Daisy's fundraising is going strong, but they still need more support.
"We're trying our best," Beth said. "A little goes a long way."
Daisy added: "Just one person donating can help a lot of people."
To donate to Beth and Daisy's fundraising effort, go to justgiving.com/page/beth-daisy.
After the challenge, they plan to celebrate with a barbecue at home - and a good night's sleep.
"I know our adrenaline will be sky high," Beth laughed.
"But it's going to be something we remember forever."
Beth and Daisy's JustGiving page is open for donations, and they're calling on local residents to lend their support.
As Daisy puts it, "If you can do it, I can do it - and together we can make a real difference."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
Ketamine's Antidepressant Action May Depend on Opioid System
Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.
Yahoo
an hour ago
- Yahoo
Postcode lottery for Mounjaro, the 'King Kong' of weight loss jabs, with only eight NHS care boards providing treatment
Thousands of severely obese patients are facing severely delayed treatment with what's been called the 'King Kong' of weight loss jabs - because the NHS rollout has been mismanaged and underfunded, according to Sky News research. Mounjaro was supposed to be available through GP surgeries and other community services from 23 June under an agreement between NHS England and the National Institute for Health and Care Excellence (NICE), the body that provides guidance on the use of new drugs. But Freedom of Information requests by Sky News reveal a postcode lottery, with only eight of 42 NHS Integrated Care Boards (ICBs) in England telling us they were providing treatment to patients, and many of the rest unable to guarantee when it would be available. The research also shows that at least 19 had a cap on how many eligible patients they would treat in the first year. Dr Jonathan Hazlehurst, an specialist at University Hospitals Birmingham, said many patients were desperate for treatment - and Mounjaro may be a hopeful aid for those eligible. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair," he said. "That's what the current system is doing." NICE said in December that the NHS should offer Mounjaro to patients with a BMI over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazelhurst says NHS England has only provided funding for just over 22,000 patients. Read more: "It shows that there's a lack of political will to fund this adequately," he said. "NHS England says that obesity costs the NHS £11.4bn per annum as a pure NHS cost. "Yet we can't even afford to properly fund the rollout of a life-changing drug in year one. That just doesn't make any sense." Gary - who doesn't want his surname used - weighs 25 stone (158kg) and becomes severely out of breath after climbing only a few stairs. He is eligible for treatment with Mounjaro under the agreed NHS guidelines. But his surgery said "no" and told him it would be at least the autumn before the drug would be available in the Hampshire area. "They said to us that September would be the earliest they going to look at it and then the criteria might change, so there's no knowing if I'm going to get it," he said. "I was so excited when I read about this drug. If I had the drug and lost some weight, it could help me move around, it could help me go fishing again, all kinds of things. "It's not for vanity. It would be a life changer." There are 3.4 million people in England who would qualify for treatment under the NICE eligibility criteria. But NHS England has said it will take 12 years to assess and prescribe to those who need it. Dr Hazlehurst said there would never be such a slow rollout with a new cancer treatment - and yet, obesity also kills. "There's a huge amount of stigma that drives things to do with obesity care all across the system," he said. "The 'eat less, move more' nonsense doesn't help. "That is a really unhelpful, harmful and stigmatising approach, particularly in an age of effective treatment." Read more from Thomas Moore: A spokesperson for NHS England said it had "fully supported the rollout" of Mounjaro. They said: "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services."
Yahoo
an hour ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
